ReviewTherapeutic advances in drug safety2019
How Clinical Practice Research Datalink data are used to support pharmacovigilance.
Review in Therapeutic advances in drug safety, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Performance of the Self-Controlled Case Series With Active Comparators for Drug Safety Signal Detection Using the Clinical Practice Research Datalink (CPRD).Pharmacoepidemiology and drug safety · 2025Article
- The Clinical Practice Research Datalink (CPRD) Mother-Baby Links: A Data Resource Profile.Pharmacoepidemiology and drug safety · 2025Article
- Article
- Developing electronic health records as a source of real-world data for veterinary pharmacoepidemiology.Frontiers in veterinary science · 2025Article
- Epidemiology and survival outcomes for liposarcoma patients in England: An observational cohort study using real world data.Rare tumors · 2025Article
- Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective Cohort.Advances in therapy · 2024Article
- Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.BMJ (Clinical research ed.) · 2024Article
- Pharmacoepidemiology: An Overview.Journal of clinical medicine · 2023Review
- Using primary care databases for addiction research: An introduction and overview of strengths and weaknesses.Addictive behaviors reports · 2022Review
- The Association between Nursing Skill Mix and Patient Outcomes in a Mental Health Setting: Protocol for an Observational Feasibility Study.International journal of environmental research and public health · 2022Article
- Article
- Pharmacovigilance: reporting requirements throughout a product's lifecycle.Therapeutic advances in drug safety · 2022Review
- Association of Enzyme-Inducing Antiseizure Drug Use With Long-term Cardiovascular Disease.JAMA neurology · 2021Article
- Use of Primary Care Data in Research and Pharmacovigilance: Eight Scenarios Where Prescription Data are Absent.Drug safety · 2021Review
- The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study.Journal of general internal medicine · 2021Observational
- Treatment patterns in pediatric patients with multiple sclerosis in Germany-a nationwide claim-based analysis.Therapeutic advances in neurological disorders · 2021Article
- Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination.Therapeutic advances in drug safety · 2021Article
- Can the Use of Bayesian Analysis Methods Correct for Incompleteness in Electronic Health Records Diagnosis Data? Development of a Novel Method Using Simulated and Real-Life Clinical Data.Frontiers in public health · 2020Article
- Identifying undetected dementia in UK primary care patients: a retrospective case-control study comparing machine-learning and standard epidemiological approaches.BMC medical informatics and decision making · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacovigilance can be defined as the science of monitoring medicines and vaccines after license for use, the purpose of which is to quantify and characterise the safety profile of a medicine, identify previously unknown adverse reactions, inform risk-benefit assessment, and support the development of actions that can be taken to reduce risks, optimise benefits and monitor their effectiveness. This review discusses the Clinical Practice Research Datalink (CPRD), which is the source of the largest research database in the UK with longitudinal, representative primary care data linked to data from other healthcare settings. CPRD supports international pharmacovigilance by providing a large, anonymised representative general population database with comprehensive capture of patient risk factors and outcomes to researchers within academic, regulatory and pharmaceutical organisations. The specific advantages of CPRD data are discussed in the context of the 'six Vs of big data' including volume, velocity, variety, veracity, validity and value. Examples of where CPRD data have been used for pharmacovigilance research and how these have fed into guidelines and policy are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.